Blood thinner or not for irregular heartbeat on dialysis
Part of Heart & circulation, Kidney & urinary, Women’s health & pregnancy clinical trials.
This study compares two ways to manage atrial fibrillation (an irregular heartbeat) in people on dialysis. One approach uses a blood thinner called apixaban, and the other does not use blood thinners. The goal is to see which approach better prevents strokes and bleeding.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have been on dialysis (hemodialysis or peritoneal) for at least 90 days.
- You have been diagnosed with atrial fibrillation (irregular heartbeat) or atrial flutter.
- Your stroke risk score is high enough (2 or more for men, 3 or more for women).
- You do not have significant bleeding risks, recent major bleeding, or need for other blood thinners.
- You are not pregnant or breastfeeding.
- You are not scheduled for a living donor kidney transplant within the next 6 months.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests apixaban (a blood thinner) to prevent stroke in people with atrial fibrillation or atrial flutter who have very poor kidney function or are on dialysis. If you qualify, you may help researchers find a safer way to lower stroke risk for this higher-risk group.
This trial compares two blood thinners, apixaban and warfarin, in people on peritoneal dialysis who have atrial fibrillation (an irregular heartbeat). The goal is to see which one works better and is safer for preventing strokes.
This trial tests whether taking a blood thinner can lower the risk of stroke in people who had atrial fibrillation (an irregular heartbeat) that happened temporarily around a stressful illness or surgery. It looks especially at people at higher risk for stroke after that episode.
This trial tests how well blood thinners (anticoagulants) work to dissolve clots in the heart of people with atrial fibrillation (an irregular heartbeat). It aims to find the best treatment for these clots before more serious complications occur.
This study follows people with atrial fibrillation to see how well blood-thinning medications work and what outcomes they experience over time. It aims to improve treatment guidance for patients with this common heart rhythm condition.
This trial follows people with atrial fibrillation to see how long-term blood-thinning treatment affects outcomes over time. It may help determine which long-term approach best lowers stroke and clot risks for patients like you.
Hear when a new Atrial fibrillation trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.